• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Background An unmet need exists for focal segmental glomerulosclerosis (FSGS) treatment.
In an 8-week, phase 2 trial, sparsentan, a dual endothelin–angiotensin receptor antagonist …

Hypertension is the leading modifiable cause of premature death and hence one of the
global targets of World Health Organization for prevention. Hypertension also affects the …

A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors
such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led …

IgA nephropathy (IgAN), the most prevalent primary glomerulonephritis worldwide, carries a
considerable lifetime risk of kidney failure. Clinical manifestations of IgAN vary from …

Background In patients with chronic kidney disease, SGLT2 inhibitors and endothelin A
receptor antagonists (ERAs) can reduce albuminuria and glomerular filtration rate (GFR) …

The endothelium is considered to be the gatekeeper of the vessel wall, maintaining and
regulating vascular integrity. In patients with chronic kidney disease, protective endothelial …

Abstract Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the latest addition to
guideline-directed medical therapy in heart failure (HF) with reduced ejection fraction with …

Improved understanding of differences in kidney disease epidemiology, management and
outcomes in men and women could help nephrologists to better meet the needs of their …